(2S)-N-[(2S,5R)-5-benzyl-6-[(2R)-2-methyloxiran-2-yl]-1-[4-[(2-methylpropan-2-yl)oxy]phenyl]-3,6-dioxohexan-2-yl]-2-[(2-morpholin-4-ylacetyl)amino]propanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-N-[(2S,5R)-5-benzyl-6-[(2R)-2-methyloxiran-2-yl]-1-[4-[(2-methylpropan-2-yl)oxy]phenyl]-3,6-dioxohexan-2-yl]-2-[(2-morpholin-4-ylacetyl)amino]propanamide
• 化学式: C₃₅H₄₇N₃O₇
• 分子量: 621.8
• InChiKey: GXAFKAWSCRWDMJ-QQZPVRTASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  45
• 可旋转键数：
  16
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• COMPOUNDS FOR ENZYME INHIBITION
  申请人：Onyx Therapeutics, Inc.

  公开号：US20140080753A1

  公开（公告）日：2014-03-20

  One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.